Three charged after drug investigation
******************************
(Canada) Two adult males and one adult female have all been charged with possession of a controlled substance and possession of a controlled substance for the purpose of trafficking. (Thu Jan 08 11:19:47 2009 PST)
Manufacturers changing dosing instruction of pain patch
******************************
(Canada) The five manufacturers of Fentanyl Transdermal Systems and Health Canada said the patches contain a high concentration of the long-acting narcotic fentanyl. The patches treat persistent, moderate to severe chronic pain in people already taking narcotic pain relievers. ... (Wed Jan 07 12:48:53 2009 PST)
Woman sought in thefts of patches
*******************
(US) Smith said she confronted Wells and asked her to take a drug test, but Wells refused and left. (Wed Jan 07 02:34:37 2009 PST)
Insulin Trial on Type 1 Diabetic Patients Completed
******************************
(US) The Company believes that the key advantages of this delivery system includes the fact that it possesses anti-inflammatory and anti-erythema properties, thus minimising skin irritation, and has the ability to provide a sustained systemic delivery of a wide range of drugs – ranging from relatively small molecules (e.g. morphine, ... (Tue Jan 06 11:19:15 2009 PST)
BDSI extends Meda's rights to pain drug
*****************
(US) US-based BioDelivery Sciences International, or BDSI, and Meda, a Swedish pharma company, have expanded their commercial partnership that provides Meda with worldwide exclusive rights to distribute the BDSI's lead product candidate Onsolis, a treatment for breakthrough pain in opioid-tolerant patients with cancer. US-based BioDelivery Sciences International, or BDSI, a... (Tue Jan 06 03:49:37 2009 PST)
JandJ Unit Recalls Pain Patches Over Defect
********************
(US) Duragesic, or fentanyl, is a potent opioid pain reliever and skin exposure directly to the gel within the patch can lead to respiratory problems and a fatal overdose. (Mon Jan 05 09:49:21 2009 PST)
BioDelivery Sciences Closes $6 Million Transaction with Meda
**********************
(Nasdaq: BDSI) and Meda AB today announced an expansion of their commercial partnership that provides Meda with worldwide exclusive rights to distribute the company s lead product candidate ONSOLIS , a treatment for breakthrough pain in opioid tolerant patients with cancer. Additionally, as a result of continuing dialogue between BDSI and Meda and their monitoring of the opioid ... (Mon Jan 05 06:48:56 2009 PST)